New Zealand Pharmaceutical Schedule - 1 March 2025

1 March 2025 - The March 2025 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...

Read more →

PHARMAC funds medicines for liver, ovarian, and neuroendocrine cancers

12 February 2025 - People with liver, ovarian, and neuroendocrine cancers will have access to more medicines from 1 March ...

Read more →

Proposal to fund a new oral contraceptive pill

3 February 2025 - PHARMAC is consulting on funding a new progestogen-only oral contraceptive pill called desogestrel (Cerazette) from 1 ...

Read more →

New Zealand Pharmaceutical Schedule - 1 February 2025

1 February 2025 - The February 2025 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...

Read more →

PHARMAC reconsiders oestradiol patch options following community feedback

29 January 2025 - PHARMAC is reviewing and reconsidering its oestradiol patch options after considerable feedback was received when it ...

Read more →

PHARMAC consulting on widening access to venetoclax, azacitidine and upadacitinib monohydrate

16 January 2025 - PHARMAC is asking for feedback on a proposal to widen access to three medicines for five ...

Read more →

2,000 people to benefit from medicine for osteoporosis and people with high blood calcium and cancer

10 January 2025 - PHARMAC is widening access to a medicine called denosumab for people with osteoporosis.  ...

Read more →

New Zealand Pharmaceutical Schedule - 1 January 2025

1 January 2025 - The January 2025 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...

Read more →

PHARMAC publishes agenda for February 2025 PTAC meeting

23 December 2024 - PHARMAC has published information on what the PTAC will be considering at its upcoming meeting in ...

Read more →

PHARMAC consulting on six medicines for New Zealanders

19 December 2024 - PHARMAC is asking for feedback on proposals to fund six medicines for cancer and antibiotic resistant ...

Read more →

PHARMAC seeks feedback to fund medicines for liver and ovarian cancer

9 December 2024 - PHARMAC is consulting on a proposal to fund bevacizumab (branded as Vegzelma) as a cancer medicine ...

Read more →

PHARMAC funds more cancer and respiratory medicines for New Zealanders

6 December 2024 - More publicly funded medicines are on the way for people with types of breast and lung ...

Read more →

New Zealand Pharmaceutical Schedule - 1 December 2024

1 December 2024 - The December 2024 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...

Read more →

New heart medicine for 18,000 New Zealanders

12 November 2024 - PHARMAC has decided to fund the medicine empagliflozin for thousands of people with a type of ...

Read more →

PHARMAC funds new medicine and removes renewal criteria for ADHD and narcolepsy treatments

11 November 2024 - PHARMAC will make two changes for people with attention deficit hyperactivity disorder (ADHD) and narcolepsy this ...

Read more →